Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zafgen Insists Life For Beloranib After Patient Death

This article was originally published in Scrip

Executive Summary

Zafgen Inc. officials on Oct. 16 did their best to try to assure investors and analysts after the FDA slapped a partial hold on the company's Phase III bestPWS (ZAF-311) trial testing its experimental severe obesity drug beloranib following the death of one of the study participants taking the medicine – with the CEO even declaring the adverse outcome was "not an unexpected finding," given the firm anticipated one to two deaths would occur.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts